Elios' customized cancer vaccine shows positive results

By The Science Advisory Board staff writers

August 5, 2020 -- Elios Therapeutics' personalized cancer vaccine shows a long-term survival benefit for patients with stage III or IV melanoma, according to final data from its clinical trial.

Three years after completing the vaccine series, 93% of high-risk melanoma patients remained alive, while 77% of patients who were given placebos survived, according to final data from a prospective, randomized, double-blind, placebo-controlled phase IIb clinical trial.

Elios' personalized tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine is made from a patient's tumor and blood. Every patient's tumor has a unique antigenic profile unlike any other, and dendritic cells found in the blood are the most potent antigen-presenting cells in the body.

Enterome begins trial for microbiome-based immunotherapy
Clinical-stage biopharmaceutical company Enterome has begun its first clinical trial for E02401, a microbiome-based cancer immunotherapy candidate.
Researchers discuss progress toward personalized cancer vaccines
Highly targeted and adaptable platforms allow researchers to develop cancer vaccines for a multitude of different cancer types and even create personalized...
Genomic landscape of osteosarcomas reveals why immunotherapy may not be effective
Immune profiling of osteosarcoma has revealed why immune checkpoint inhibitors might not be an effective treatment option for patients with this rare...
Improving melanoma immunotherapies by regulating Treg proliferation
A new pathway to regulating anti-tumor immunity and increasing the effectiveness of PD-1 therapies was identified by scientists at Sanford Burnham Prebys...
A discovery of fungi – helping researchers identify new drugs
To address the need to identify new therapeutic targets, researchers at the Hubrecht Institute turned to fungi. The researchers tested secondary metabolites...

Copyright © 2020 scienceboard.net

Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
ESMO Virtual Congress 2020
September 14-29
2020 ACCP Annual Meeting
September 20-22
BioProcess International West
September 21-25
BioProcess International
September 21-25
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter